Filing Flows › Aurinia Pharmaceuticals (AUPH) › Q3 2026 › vs Q3 2025
Aurinia Pharmaceuticals (AUPH) Q3 2026 vs Q3 2025 (year over year)
Aurinia Pharmaceuticals's revenue rose $10.2M (+14%) from $73.5M in Q3 2025 to $83.7M in Q3 2026. The biggest changes: Net product sales +$8.8M (+12%); License, collaboration and royalty revenue +$1.4M (+51%). Operating margin 42.3% against 40.5% (+1.8 pts).
Aurinia Pharmaceuticals, Q3 2026: revenue $83.7M (+14% year over year), operating margin 42.3%, net earnings $31.7M, operating cash flow $46.4M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Operating margin | 42.3% | 40.5% | +1.8 pts |
| Net margin | 37.9% | 42.9% | -5.1 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Net product sales | $79.4M | $70.6M | $8.8M | +12% |
| License, collaboration and royalty revenue | $4.3M | $2.8M | $1.4M | +51% |
| Revenue | $83.7M | $73.5M | $10.2M | +14% |
| Other income, net | $3.4M | $2.2M | $1.1M | +51% |
| Operating profit | $35.4M | $29.7M | $5.6M | +19% |
| Costs & expenses | $48.3M | $43.7M | $4.6M | +11% |
| Pre-tax earnings | $38.7M | $32.0M | $6.8M | +21% |
| Net earnings | $31.7M | $31.6M | $152K | +0.5% |
| Income tax | $7.0M | $411K | $6.6M | 17× |
| Depreciation & amortization | $4.8M | $4.9M | −$24K | -0.5% |
| Share-based compensation | $6.1M | $5.9M | $205K | +3% |
| Working capital & other | $3.7M | $2.1M | $1.6M | +75% |
| Operating cash flow | $46.4M | $44.4M | $1.9M | +4% |
Questions
How much did Aurinia Pharmaceuticals's revenue grow year over year in Q3 2026?
Aurinia Pharmaceuticals's revenue rose $10.2M (+14%) from $73.5M in Q3 2025 to $83.7M in Q3 2026.
What drove Aurinia Pharmaceuticals's revenue change in Q3 2026?
Net product sales +$8.8M (+12%); License, collaboration and royalty revenue +$1.4M (+51%).